Portfolio Design Labs LLC Invests $1.35 Million in Stryker Corporation $SYK

Portfolio Design Labs LLC purchased a new stake in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 4,281 shares of the medical technology company’s stock, valued at approximately $1,348,000.

A number of other institutional investors have also recently modified their holdings of SYK. Gables Capital Management Inc. purchased a new position in Stryker in the second quarter worth $25,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker during the 4th quarter worth $26,000. Sankala Group LLC purchased a new stake in shares of Stryker during the 4th quarter worth $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter worth $27,000. Finally, Atlas Capital Advisors Inc. purchased a new position in shares of Stryker in the 4th quarter valued at about $27,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on SYK. BMO Capital Markets started coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Argus set a $370.00 price target on Stryker in a research note on Thursday, July 9th. Needham & Company LLC lowered their price target on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, Citizens Jmp dropped their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Performance

NYSE SYK opened at $327.97 on Friday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The business has a fifty day moving average of $326.64 and a 200-day moving average of $332.66. The stock has a market cap of $125.80 billion, a price-to-earnings ratio of 33.99, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is 36.48%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 665,370 shares of company stock worth $216,238,501 over the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.